Jackson Creek Investment Advisors LLC bought a new stake in AbCellera Biologics Inc. (NASDAQ:ABCL – Get Rating) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 83,634 shares of the company's stock, valued at approximately $827,000.
Several other large investors also recently added to or reduced their stakes in the stock. Toronto Dominion Bank purchased a new stake in AbCellera Biologics in the 3rd quarter valued at $35,000. IFP Advisors Inc purchased a new stake in AbCellera Biologics in the 3rd quarter valued at $64,000. New York State Common Retirement Fund grew its holdings in AbCellera Biologics by 1.2% in the 3rd quarter. New York State Common Retirement Fund now owns 145,145 shares of the company's stock valued at $1,435,000 after buying an additional 1,745 shares in the last quarter. Virtu Financial LLC acquired a new position in shares of AbCellera Biologics in the 3rd quarter valued at $149,000. Finally, Quantbot Technologies LP lifted its stake in shares of AbCellera Biologics by 32.8% in the 3rd quarter. Quantbot Technologies LP now owns 86,460 shares of the company's stock valued at $855,000 after purchasing an additional 21,351 shares during the last quarter. 42.19% of the stock is currently owned by hedge funds and other institutional investors.
Get AbCellera Biologics alerts:AbCellera Biologics Trading Down 1.9 %
ABCL opened at $10.97 on Tuesday. The stock's 50-day moving average price is $10.54 and its 200 day moving average price is $11.12. AbCellera Biologics Inc. has a 12-month low of $5.42 and a 12-month high of $14.97. The firm has a market cap of $3.14 billion, a price-to-earnings ratio of 13.89 and a beta of -0.16.
AbCellera Biologics (NASDAQ:ABCL – Get Rating) last posted its earnings results on Tuesday, November 8th. The company reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.01). AbCellera Biologics had a return on equity of 21.15% and a net margin of 41.17%. The firm had revenue of $101.38 million for the quarter, compared to analyst estimates of $77.19 million. On average, research analysts forecast that AbCellera Biologics Inc. will post 0.62 earnings per share for the current year.Insiders Place Their Bets
In related news, major shareholder Holdings Ltd. Thermopylae purchased 85,102 shares of the business's stock in a transaction on Friday, December 16th. The shares were bought at an average price of $10.10 per share, for a total transaction of $859,530.20. Following the acquisition, the insider now directly owns 55,859,493 shares in the company, valued at $564,180,879.30. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 30.30% of the stock is owned by company insiders.
Analysts Set New Price Targets
Several equities analysts have recently commented on the company. The Goldman Sachs Group assumed coverage on AbCellera Biologics in a research note on Thursday, December 15th. They issued a "buy" rating and a $30.00 price target on the stock. Piper Sandler decreased their price target on AbCellera Biologics from $22.00 to $21.00 in a research note on Tuesday, November 1st. Truist Financial assumed coverage on AbCellera Biologics in a research note on Wednesday, November 16th. They issued a "buy" rating and a $29.00 price target on the stock. Finally, SVB Leerink decreased their price target on AbCellera Biologics from $20.00 to $18.00 and set an "outperform" rating on the stock in a research note on Friday, January 6th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $28.67.
About AbCellera Biologics
(Get Rating)
AbCellera Biologics Inc develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners.
Read More
- Get a free copy of the StockNews.com research report on AbCellera Biologics (ABCL)
- Why Is Wall Street Loving Amazon So Much?
- Want to Invest in ChatGPT? Then Buy Microsoft Stock
- Anhui Conch: Opportunity With Cement Solid Cash Flows
- Is Biotech Immunocore About To Make A 25% Price Move?
- Is Merck Stock a Buy After Its Post-Earnings Sell-Off?
Want to see what other hedge funds are holding ABCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbCellera Biologics Inc. (NASDAQ:ABCL – Get Rating).
Receive News & Ratings for AbCellera Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbCellera Biologics and related companies with MarketBeat.com's FREE daily email newsletter.